^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Published date:
03/02/2023
Excerpt:
A percutaneous biopsy on the left neck indicated a pathological diagnosis of T4N3M1c (IVB) metastatic lung adenocarcinoma....The liver metastases lesion and ctDNA were performed by NGS analysis and detected EML4-ALK fusion (level, plasma 0.24%) again, accompanied by an acquired ALK resistance mutation (ALK I1171N)...the patient then took ensartinib as the second-line treatment immediately post alectinib. Surprisingly, 20 days later, CT re-examination showed that the multiple tiny nodules in both lungs were roughly the same as before, ultrasound re-examination revealed that most of the multiple lesions in the liver were reduced compared to before...
DOI:
https://doi.org/10.1186/s12957-023-02935-9